Cenobamate for treating focal onset seizures in epilepsy (TA753)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 July 2025Published: 15 December 2021
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2025
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2025
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 March 2023
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 July 2022
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019